A new cytokine-based dynamic stratification during induction is highly predictive of survivals in acute myeloid leukemia.
FLT3 ligand
IL-6
acute myeloid leukemia
prognostic biomarker
Journal
Cancer medicine
ISSN: 2045-7634
Titre abrégé: Cancer Med
Pays: United States
ID NLM: 101595310
Informations de publication
Date de publication:
01 2021
01 2021
Historique:
received:
17
04
2020
revised:
29
10
2020
accepted:
19
11
2020
pubmed:
29
12
2020
medline:
20
7
2021
entrez:
28
12
2020
Statut:
ppublish
Résumé
The aim of this study was to assess the potential impact of the kinetics of serum levels of seven cytokines during induction in acute myeloid leukemia (AML) patients. Indeed, the role of cytokines, in the pathophysiology and response to therapy of AML patients, remains under investigation. Here, we report on the impact of peripheral levels of two cytokines, the Fms-like tyrosine kinase 3 ligand (FL) and interleukin-6 (IL-6), evaluated during first-line intensive induction. A new risk stratification can be proposed, which supersedes the ELN 2017 classification to predict survivals in AML patients by examining the kinetic profile of these cytokines during the induction phase. It segregates three groups of, respectively, high-risk, characterized by a stagnation of low FL levels, intermediate risk, with dynamic increasing FL levels and high IL-6 at day 22, and favorable risk with increasing FL levels but low IL-6 at day 22.
Identifiants
pubmed: 33369136
doi: 10.1002/cam4.3648
pmc: PMC7877358
doi:
Substances chimiques
Biomarkers, Tumor
0
IL6 protein, human
0
Interleukin-6
0
Membrane Proteins
0
flt3 ligand protein
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
642-648Informations de copyright
© 2020 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
Références
Blood Adv. 2017 Aug 01;1(18):1387-1397
pubmed: 29296780
Haematologica. 2019 Jun;104(6):e240-e243
pubmed: 30630980
J Hematother Stem Cell Res. 2002 Jun;11(3):533-8
pubmed: 12183838
Blood Adv. 2019 Oct 22;3(20):3052-3061
pubmed: 31648336
Hum Immunol. 2014 Feb;75(2):113-8
pubmed: 24269703
Exp Oncol. 2014 Mar;36(1):50-1
pubmed: 24691286
Cell Rep. 2017 Mar 28;18(13):3204-3218
pubmed: 28355571
Cytokine. 2013 Mar;61(3):885-91
pubmed: 23357299
Blood. 2010 Nov 18;116(20):4251-61
pubmed: 20679526
Cytokine Growth Factor Rev. 2018 Oct;43:8-15
pubmed: 30181021
Int J Mol Sci. 2017 May 24;18(6):
pubmed: 28538663
J Immunother Cancer. 2017 Nov 21;5(1):85
pubmed: 29157295
Leukemia. 2009 Feb;23(2):350-7
pubmed: 18987664
Neoplasia. 2013 Jul;15(7):848-62
pubmed: 23814496
EBioMedicine. 2019 Feb;40:240-250
pubmed: 30662003